Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Radiation boosts standard therapy in metastatic breast cancer trial

NCT ID NCT04563507

First seen Jan 04, 2026 · Last updated Jun 12, 2026 · Updated 23 times

Summary

This study is for women with a common type of advanced breast cancer (HR+ HER2-). It tests whether adding targeted radiation to each tumor site, along with standard hormone therapy and a targeted drug, can help keep the cancer from growing longer. About 102 participants will be randomly assigned to receive radiation or not, and researchers will track how long the cancer stays controlled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brooklyn Methodist Hospital - NewYork Presbyterian

    RECRUITING

    New York, New York, 11215, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • New York Presbyterian Hospital - Queens

    RECRUITING

    New York, New York, 11355, United States

    Contact

    Contact Email: •••••@•••••

    Contact

  • Weill Cornell Medicine

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.